Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

Journal of Controlled Release

Volumn 39, Issue 2-3, 1996, Pages 139-143

  Benet, Leslie Z ^a   Wu, Chi Yuan ^a   Hebert, Mary F ^a   Wacher, Vincent J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AuMax Inc   (United States)

Author keywords

Counter transport; Cyclosporin; Cytochrome P450 3A; Gut metabolism; P glycoprotein

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450;

CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TRANSFORMATION; DRUG TRANSPORT; HUMAN; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030002504     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00147-6     Document Type: Conference Paper

References (12)

1. B. Hoener and L.Z. Benet, Factors influencing drug absorption and drug availability, in: G.S. Banker and C.T. Rhodes (Eds), Modern Pharmaceutics, 3rd Edn, Marcel Dekker, New York, 1996, pp. 121-153.
2. M. Rowland and T.N. Tozer, in: Clinical Pharmacokinetics: Concepts and Applications, 3rd Edn, Chapter 9, Williams and Wilkins, Baltimore, 1995, pp. 119-136.
3. Y.K. Tam, Individual variation in first-pass metabolism, Clin. Pharmacokinet. 25 (1993) 300-328 .
4. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan and M.C. Willingham, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues, Proc. Natl. Acad. Sci. USA 84 (1987) 7735-7738.
5. P.B. Watkins, S.A. Wrighton, E.G. Schuetz, D.T. Molowa and P.S. Guzelian, Identification of glucocorticoid-inducible cytochromes P-450 in intestinal mucosa of rats and man. J. Clin. Invest. 80 (1987) 1029-1036.
6. J.C. Kolars, P. Schmiedlin-Ren, J.D. Schuetz, C. Fang and P.B. Watkins, Identification of rifampin-inducible P450IIIA4 (CYP 3A4) in human small bowel enterocytes. J. Clin. Invest. 90 (1992) 1871-1878.
7. J.C. Kolars, W.M. Awni, R.M. Merion and P.B. Watkins, First-pass metabolism of cyclosporin by the gut, Lancet 338 (1991) 1488-1490.
8. V.J. Wacher, C.Y. Wu and L.Z. Benet, Overlapping substrate specificities and tissue distribution of cytochrome P-450 3A and P-glycoprotein have implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog. 13 (1995) 129-134.
9. C.Y. Wu, M.F. Hebert and L.Z. Benet, Use of i.v. and oral drug levels from cyclosporine (CsA) with concomitant rifampin to differentiate gut absorption and metabolism, Pharm. Res. 10 (1993) S345.
10. C.Y. Wu, L.Z. Benet, M.F. Hebert, S.K. Gupta, M. Rowland, D.Y. Gomez and V.J. Wacher, Differentiation of absorption, first-pass gut and hepatic metabolism in man: studies with cyclosporine, Clin. Pharmacol. Ther. 58 (1995) 492-497.
11. M.F. Hebert, J.P. Roberts, T. Prueksaritanont and L.Z. Benet, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction, Clin. Pharmacol. Ther. 52 (1992) 453-455.
12. D.Y. Gomez, V.J. Wacher, S.J. Tomlanovich, M.F. Hebert and L.Z. Benet, The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine, Clin. Pharmacol. Ther. 58 (1995) 15-19.